> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Expanded Access Program for Promising Pancreatic Cancer Drug
- URL: https://www.fdaweb.com/expanded-access-program-for-promising-pancreatic-cancer-drug/
- Published: 2026-05-01T12:00:00.000Z
- Updated: 2026-09-14T13:38:27.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161080

FDA has [authorized](https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug?utm%5Fmedium=email&utm%5Fsource=govdelivery) an expanded access program for an experimental pancreatic cancer therapy from Revolution Medicines, allowing certain patients to receive the drug outside of clinical trials. The agency said it issued a “safe to proceed” letter enabling the company to launch an expanded access treatment protocol for daraxonrasib, a RAS inhibitor being developed for patients with previously treated metastatic pancreatic ductal adenocarcinoma.

The decision came just two days after FDA received the request on 4/28, underscoring what officials described as an effort to accelerate access to investigational therapies for serious and life-threatening conditions.

The therapy has been in the news lately after former Sen. **Ben Sasse** revealed he’s been taking it. Late last year, Sasse announced he was diagnosed with Stage 4 pancreatic cancer and given three to four months to live. This week, he indicated that his tumors have shrunk by 76% since he started the treatment, but it has also caused a rash on his skin.

Daraxonrasib is designed to target mutations in the RAS protein, which are commonly found in pancreatic cancer tumors. The drug, also known as RMC-6236, has previously received breakthrough therapy and orphan drug designations from the FDA. Revolution Medicines has indicated it plans to submit an NDA under the agency’s National Priority Voucher pilot program.